Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.49 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9288287 | 0.94 | CASP2 (0.55) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL9285562 | 0.94 | CASP2 (0.55) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL9289436 | 0.93 | NAAA (0.46) | NAAADNM1CASP2PAOXEPHX1 | |
| SCHEMBL21758430 | 0.93 | NAAA (0.46) | NAAADNM1CASP2PAOXEPHX1 | |
| SCHEMBL19040774 | 0.91 | CASP2 (0.58) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL6120261 | 0.88 | CASP2 (0.51) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL23576154 | 0.87 | CASP2 (0.55) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL20589913 | 0.87 | CASP2 (0.55) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL12201188 | 0.87 | CASP2 (0.58) | NAAADNM1CASP2EPHX1FAAH | |
| SCHEMBL1037232 | 0.87 | SLC6A5 (0.47) | NAAADNM1CASP2PAOXEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2023-06-15 | — | — | US | disclosed |
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2023-06-15 | — | — | US | disclosed |
| US-20200061197-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2020-02-27 | — | — | US | disclosed |
| US-10406237-B2 | Amine-containing transfection reagents and methods for making and using same | LIFE TECHNOLOLGIES CORPORATION (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3470395-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20180200374-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2018-07-19 | — | — | US | disclosed |
| US-9901642-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2018-02-27 | — | — | US | disclosed |
| US-20150174260-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation | 2015-06-25 | — | — | US | disclosed |
| US-20120136073-A1 | Amine-Containing Transfection Reagents and methods for making and using same | Life Technologies Corporation (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012068176-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | Life Technologies Corporation (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174260-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | NAAA 99/4885DNM1 2014/4885CASP2 1820/4885 |
| US-10406237-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | NAAA 99/4885DNM1 2014/4885CASP2 1820/4885 |
| US-20230181742-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | NAAA 99/4885DNM1 2014/4885CASP2 1820/4885 |
| US-20200061197-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | NAAA 99/4885DNM1 2014/4885CASP2 1820/4885 |
| US-20120136073-A1 | Amine-Containing Transfection Reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | NAAA 99/4885DNM1 2014/4885CASP2 1820/4885 |
| US-20180200374-A1 | AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME | SNRPA, NUDT21, SOAT2 | NAAA 99/4885DNM1 2014/4885CASP2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.